0
J&J and Bayer’s Xarelto wins where Pfizer drug lost – FierceBiotech
![]() ThirdAge |
J&J and Bayer's Xarelto wins where Pfizer drug lost
FierceBiotech The blood-thinner Xarelto has added some upbeat Phase III data to its resume. Bayer ($ BAYN), which is co-developing the drug with Johnson & Johnson ($ JNJ), said the drug met its primary efficacy endpoint in sufferers of acute coronary syndrome. … Bayer, J&J's Xarelto Helped Acute Coronary Syndrome Patients Xarelto Found to Help Angina and Heart Attack Patients Bayer, J&J Blood Thinner Rivaroxaban Met Primary Goal In Phase III Trial |






